Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]

602 reported adverse events

Drugs of this class: TEBENTAFUSP

These side effects are most commonly reported by patients taking drugs of the Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] class:

# Side effect Count
0 CYTOKINE RELEASE SYNDROME 118
1 PYREXIA 107
2 DISEASE PROGRESSION 73
3 HYPOTENSION 70
4 RASH 69
5 MALIGNANT NEOPLASM PROGRESSION 61
6 CHILLS 59
7 PRODUCT DOSE OMISSION ISSUE 56
8 PRURITUS 44
9 NAUSEA 40
See all common reactions for Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]

Drugs of the Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HEPATOBILIARY NEOPLASM 1 0.1000
1 UVEAL MELANOMA 5 0.0893
2 ANTERIOR SEGMENT NEOVASCULARISATION 1 0.0833
3 EXERTIONAL RHABDOMYOLYSIS 3 0.0811
4 METASTATIC OCULAR MELANOMA 2 0.0800
5 DELAYED ISCHAEMIC NEUROLOGICAL DEFICIT 1 0.0476
6 CHOROIDAL DYSTROPHY 1 0.0208
7 ACHROMOTRICHIA ACQUIRED 1 0.0204
8 EYELASH DISCOLOURATION 4 0.0183
9 CHOROID MELANOMA 2 0.0177
See all enriched reactions for Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]